Gamida Cell Ltd.
DelistedCIK 1600847fmd_06YPRCTF5DPSDCRXD8HRBE63ACManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Mar 31, 2024, 22 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 2 |
| Cost of revenue | – | – | – | – | – | – | – | 1 |
| Gross profit | – | – | – | – | – | – | – | 0 |
| Research and development | 19 | 15 | 22 | 31 | 1 | 50 | 43 | 24 |
| Selling, general and administrative | – | – | – | – | – | – | 32 | 45 |
| Total operating expenses | – | – | – | – | – | – | 75 | 73 |
| Operating income | (24) | (19) | (34) | (48) | (61) | (87) | (75) | (73) |
| Interest expense | 0 | 1 | 20 | 3 | 11 | – | 6 | 8 |
| Interest and investment income | – | – | – | – | – | – | 3 | 3 |
| Other non-operating income (expense) | – | – | – | – | (1) | (3) | (4) | 10 |
| Income before taxes | – | (19) | (53) | (34) | 62 | 0 | 0 | – |
| Income tax expense | 0 | 0 | 0 | (0) | – | – | – | – |
| Net income from continuing operations | – | (19) | (53) | (34) | – | – | – | – |
| Net income | (23) | (19) | (53) | (34) | (62) | (90) | (79) | (63) |
| Net income to common shareholders | – | – | – | – | – | 90 | 79 | 63 |